


Levocabastine hydrochloride

| | |
|---------------------------|--|
| Cat. No.: | HY-14277A |
| CAS No.: | 79547-78-7 |
| Molecular Formula: | C ₂₆ H ₃₀ ClFN ₂ O ₂ |
| Molecular Weight: | 456.98 |
| Target: | Histamine Receptor; Neurotensin Receptor; Integrin |
| Pathway: | GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Cytoskeleton |
| Storage: | -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



SOLVENT & SOLUBILITY

| | |
|----------------|--|
| In Vivo | <ol style="list-style-type: none"> Add each solvent one by one: DMSO Solubility: 4.5 mg/mL (9.85 mM); Clear solution; Need ultrasonic and warming Add each solvent one by one: PBS Solubility: 0.33 mg/mL (0.72 mM); Clear solution; Need ultrasonic and warming |
|----------------|--|

BIOLOGICAL ACTIVITY

| | | |
|-------------------------------------|---|---------------------------------|
| Description | Levocabastine (R 50547) hydrochloride is a potent and selective histamine H ₁ -receptor antagonist. Levocabastine hydrochloride is also a selective, high affinity neurotensin receptor subtype 2 (NTR2) antagonist, with a K _i of 17 nM for mNTR2. Levocabastine hydrochloride can act as a VLA-4 antagonist, interferes with conjunctival eosinophil infiltration in allergic conjunctivitis (AC) ^{[1][2][3]} . | |
| IC₅₀ & Target | H ₁ Receptor | NTR2 17 nM (K _i) |
| In Vitro | Levocabastine (0-1000 μM; HEK-293 cells) hydrochloride causes inhibition of ¹²⁵ I-FN binding to the SPA bead-associated α4β1 integrin in a concentration-dependent manner with an IC ₅₀ of 406.2 μM ^[3] . Levocabastine (0-1000 μM; 30 min; Jurkat cells and EoL-1 cells) hydrochloride inhibits α4β1 integrin/VCAM-1-mediated cell adhesion in vitro. Levocabastine inhibits α4β1 integrin-independent adhesion of Jurkat cells to VCAM-1 with an IC ₅₀ of 395.6 μM, and the adhesion of EoL-1 cells with an IC ₅₀ of 403.6 μM. Moreover, Levocabastine inhibits adhesion of human eosinophils to VCAM-1-coated wells (IC ₅₀ =443.7 μM) ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| In Vivo | Levocabastine (R 50547; 0.25 mg/kg; i.p.; twice a day for five days; guinea-pig with Parainfluenza-3 (PI-3) virus) hydrochloride inhibits the virus-induced airway hyperresponsiveness ^[1] . Levocabastine (0.05 mg/kg; i.p.; once; male C57BL/6J mice) hydrochloride blocks anti-stress effect of β-LT on mouse behavior ^[2] . Levocabastine (500 μg/eye; drops eye; once; ovalbumin-sensitized guinea pigs) hydrochloride induces allergic conjunctivitis (AC) and a significant increase of conjunctival VLA-4 ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |

| | |
|-----------------|---|
| Animal Model: | Guinea-pig with Parainfluenza-3 (PI-3) virus ^[1] |
| Dosage: | 0.25 mg/kg |
| Administration: | Intraperitoneal injection; twice a day for five days |
| Result: | Suppressed the influx of broncho-alveolar cells and increased in albumin content. |
| Animal Model: | Male C57BL/6J mice (8-9 weeks old) ^[2] |
| Dosage: | 0.05 mg/kg; 30 mg/kg (β -LT) |
| Administration: | Intraperitoneal injection; once |
| Result: | Blocked the anxiolytic effect of β -LT and decreased the number of head-dips. |
| Animal Model: | Ovalbumin-sensitized guinea pigs ^[3] |
| Dosage: | 500 μ g/eye |
| Administration: | drops eye, once |
| Result: | Produced a noteworthy protection from allergic conjunctivitis (AC) and prevented the conjunctival elevation of VLA-4 as well as conjunctival eosinophil infiltration. |

REFERENCES

- [1]. Folkerts G, et, al. Virus-induced airway hyperresponsiveness in the guinea-pig: possible involvement of histamine and inflammatory cells. *Br J Pharmacol.* 1993 Apr;108(4):1083-93.
- [2]. Yamauchi R, et, al. Effect of beta-lactotensin on acute stress and fear memory. *Peptides.* 2006 Dec;27(12):3176-82.
- [3]. Qasem AR, et, al. Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. *Biochem Pharmacol.* 2008 Sep 15;76(6):751-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA